Eliminating antibody polyreactivity through addition of N-linked glycosylation

Protein Science

Volumn 24, Issue 6, 2015, Pages 1019-1030

  Chuang, Gwo Yu ^a   Zhang, Baoshan ^a   McKee, Krisha ^a   O'Dell, Sijy ^a   Kwon, Young Do ^a   Zhou, Tongqing ^a   Blinn, Julie ^b   Lloyd, Krissey ^b   Parks, Robert ^b   Von Holle, Tarra ^b   Ko, Sung Youl ^a   Kong, Wing Pui ^a   Pegu, Amarendra ^a   Wang, Keyun ^a   Baruah, Kavitha ^c   Crispin, Max ^c   Mascola, John R ^a   Moody, M Anthony ^b   Haynes, Barton F ^b   Georgiev, Ivelin S ^a   Kwong, Peter D ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

antibody engineering; bioinformatics; broadly neutralizing antibody; glycan engineering; polyreactivity

Indexed keywords

AUTOANTIGEN; CARDIOLIPIN; GLYCAN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VRC 07 ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY ENGINEERING; ANTIBODY POLYREACTIVITY; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GLYCOSYLATION; HEP 2 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; GENETICS; HEP-G2 CELL LINE; HUMAN; IMMUNOLOGY; MUTATION; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; GLYCOSYLATION; HEP G2 CELLS; HIV ANTIBODIES; HUMANS; MICE; MUTATION; PROTEIN ENGINEERING;

EID: 84946196156     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2682     Document Type: Article

References (40)

1. Mejias A, Ramilo O, (2008) Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biol Targets Ther 2: 433-439.
2. Chan AC, Carter PJ, (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301-316.
3. Leavy O, (2010) Therapeutic antibodies: past, present and future. Nat Rev Immunol 10: 297.
4. Weiner LM, Surana R, Wang S, (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327.
5. Scott AM, Wolchok JD, Old LJ, (2012) Antibody therapy of cancer. Nat Rev Cancer 12: 278-287.
6. Baker MP, Jones TD, (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Dev 10: 219-227.
7. Beck A, Wurch T, Bailly C, Corvaia N, (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10: 345-352.
8. Diskin R, Scheid JF, Marcovecchio PM, West AP, Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ, (2011) Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334: 1289-1293.
9. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K, (2011) Engineering the variable region of therapeutic IgG antibodies. MAbs 3: 243-252.
10. Derer S, Kellner C, Berger S, Valerius T, Peipp M, (2012) Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function. Methods Mol Biol 907: 519-536.
11. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J, Program NCS, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ, (2014) Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88: 12669-12682.
12. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchere E, Coutinho A, Kazatchkine MD, (1998) Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216: 117-137.
13. Notkins AL, (2004) Polyreactivity of antibody molecules. Trends Immunol 25: 174-179.
14. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM, (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
15. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L, Program NCS, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF, (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-476.
16. Bonsignori M, Wiehe K, Grimm SK, Lynch R, Yang G, Kozink DM, Perrin F, Cooper AJ, Hwang KK, Chen X, Liu M, McKee K, Parks RJ, Eudailey J, Wang M, Clowse M, Criscione-Schreiber LG, Moody MA, Ackerman ME, Boyd SD, Gao F, Kelsoe G, Verkoczy L, Tomaras GD, Liao HX, Kepler TB, Montefiori DC, Mascola JR, Haynes BF, (2014) An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest 124: 1835-1843.
17. Zhou ZH, Tzioufas AG, Notkins AL, (2007) Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun 29: 219-228.
18. Porcheray F, Fraser JW, Gao B, McColl A, DeVito J, Dargon I, Helou Y, Wong W, Girouard TC, Saidman SL, Colvin RB, Palmisano A, Maggiore U, Vaglio A, Smith RN, Zorn E, (2013) Polyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement. Am J Transplant 13: 2590-2600.
19. Sigounas G, Harindranath N, Donadel G, Notkins AL, (1994) Half-life of polyreactive antibodies. J Clin Immunol 14: 134-140.
20. Thomson AH, (2000) Introduction to clinical pharmacokinetics. Paed Perinatal Drug Ther 4: 3-11.
21. Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL, (1994) Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J Immunol 152: 5988-5996.
22. Song R, Oren DA, Franco D, Seaman MS, Ho DD, (2013) Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nat Biotechnol 31: 1047-1052.
23. Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, Jacobs SA, Teplyakov A, Gilliland GL, Feng Y, (2010) Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel 23: 643-651.
24. Hanson SR, Culyba EK, Hsu TL, Wong CH, Kelly JW, Powers ET, (2009) The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc Natl Acad Sci USA 106: 3131-3136.
25. Zheng K, Bantog C, Bayer R, (2011) The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 3: 568-576.
26. Zhu Z, Ramakrishnan B, Li J, Wang Y, Feng Y, Prabakaran P, Colantonio S, Dyba M, Qasba P, Dimitrov D, (2014) Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs 6: 1190-1200.
27. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR, (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
28. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD, (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817.
29. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC, (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637.
30. Chuang GY, Boyington JC, Joyce MG, Zhu J, Nabel GJ, Kwong PD, Georgiev I, (2012) Computational prediction of N-linked glycosylation incorporating structural properties and patterns. Bioinformatics 28: 2249-2255.
31. Haynes BF, Verkoczy L, Kelsoe G, (2014) Redemption of autoreactive B cells. Proc Natl Acad Sci USA 111: 9022-9023.
32. Sabouri Z, Schofield P, Horikawa K, Spierings E, Kipling D, Randall KL, Langley D, Roome B, Vazquez-Lombardi R, Rouet R, Hermes J, Chan TD, Brink R, Dunn-Walters DK, Christ D, Goodnow CC, (2014) Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Proc Natl Acad Sci USA 111: E2567-E2575.
33. Pan LQ, Wang HB, Lai J, Xu YC, Zhang C, Chen SQ, (2013) Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Biomaterials 34: 9115-9123.
34. West AP, Jr, Diskin R, Nussenzweig MC, Bjorkman PJ, (2012) Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 109: E2083-E2090.
35. Breiman L, (2001) Random forests. Machine Learn 45: 5-32.
36. Laskowski RA, MacArthur MW, Moss DS, Thorton JM, (1993) PROCHECK-a program to check the stereochemical quality of protein structures. J Appl Cryst 26: 283-291.
37. Xiang Z, Honig B, (2001) Extending the accuracy limits of prediction for side-chain conformations. J Mol Biol 311: 421-430.
38. Jacobson MP, Friesner RA, Xiang Z, Honig B, (2002) On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 320: 597-608.
39. Wu L, Zhou T, Yang ZY, Svehla K, O'Dell S, Louder MK, Xu L, Mascola JR, Burton DR, Hoxie JA, Doms RW, Kwong PD, Nabel GJ, (2009) Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J Virol 83: 5077-5086.
40. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, Wang K, Bao S, Kraemer TD, Rath T, Zeng M, Schmidt SD, Todd JP, Penzak SR, Saunders KO, Nason MC, Haase AT, Rao SS, Blumberg RS, Mascola JR, Nabel GJ, (2014) Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514: 642-645.